Yousif Capital Management LLC Cuts Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Yousif Capital Management LLC cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 18.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,422 shares of the medical equipment provider’s stock after selling 7,896 shares during the quarter. Yousif Capital Management LLC’s holdings in Zimmer Biomet were worth $4,189,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. American Century Companies Inc. increased its position in shares of Zimmer Biomet by 21.2% during the third quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock worth $545,809,000 after acquiring an additional 852,186 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of Zimmer Biomet by 4.9% during the third quarter. Victory Capital Management Inc. now owns 3,080,463 shares of the medical equipment provider’s stock worth $345,690,000 after acquiring an additional 144,147 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Zimmer Biomet by 16.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,760,021 shares of the medical equipment provider’s stock worth $335,895,000 after acquiring an additional 386,019 shares during the last quarter. Boston Partners increased its position in shares of Zimmer Biomet by 29.2% during the third quarter. Boston Partners now owns 2,694,832 shares of the medical equipment provider’s stock worth $302,366,000 after acquiring an additional 608,959 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Zimmer Biomet by 4.5% during the third quarter. Northern Trust Corp now owns 2,653,334 shares of the medical equipment provider’s stock worth $297,757,000 after acquiring an additional 113,139 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. StockNews.com lowered Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a report on Monday, February 19th. Truist Financial boosted their price objective on Zimmer Biomet from $133.00 to $135.00 and gave the company a “hold” rating in a report on Friday, February 9th. Citigroup boosted their price objective on Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. Evercore ISI boosted their price objective on Zimmer Biomet from $125.00 to $130.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. Finally, TheStreet raised Zimmer Biomet from a “c” rating to a “b-” rating in a report on Thursday, February 8th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $139.39.

Insider Activity

In other news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the sale, the vice president now owns 44,145 shares in the company, valued at approximately $5,677,929.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.95% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $119.35 on Friday. The stock has a fifty day moving average price of $125.98 and a two-hundred day moving average price of $119.52. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61. The firm has a market cap of $24.52 billion, a P/E ratio of 24.41, a PEG ratio of 2.20 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.00 and a 1 year high of $149.25.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, beating analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. During the same quarter in the prior year, the firm earned $1.88 EPS. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.80%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 19.63%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.